View Document Preview and Link Document Date: 2014-01-27 10:24:36 Open Document File Size: 66,92 KB Share Result on Facebook
Company Ontario Government Pharmaceutical / GlaxoSmithKline Inc. / Merck Frosst Canada Ltd. / / Country Canada / / IndustryTerm weakened immune systems / blood products / / MedicalCondition breakthrough disease / varicella vaccines / anaphylactic reaction / varicella disease / varicella breakthrough cases / allergies / pneumonia / minor infection / mumps / severe acute febrile illness / disease / chickenpox / ear infections / varicella vaccine / measles / chickenpox infection / monovalent varicella vaccine / varicella vaccine program / varicella immunization series / varicella cases / bacterial skin infections / varicella immunization program / childhood disease / rubella / monovalent varicella vaccines / varicella encephalitis / varicella vaccination / varicella schedule / infection / univalent varicella vaccine / varicella vaccine high-risk criteria / varicella / zoster / / MedicalTreatment immunization / active immunization / vaccination / / Organization Canada’s National Advisory Committee on Immunization / National Advisory Committee on Immunization / Public Health Agency of Canada / Ministry of Health / Medical Supply Service / / Position Queen / Governor / / ProvinceOrState Ontario / / Technology html / pdf / / URL http / SocialTag 
Microsoft Word - 1_Attachment E - QsAs_ 2-dose varicella_June_20_11.doc